立康生命科技：个性化mRNA肿瘤疫苗技术转化落地，开创AI+个性化肿瘤免疫治疗新纪元

Core Insights - The article highlights the emergence of personalized immunotherapy as a key direction in overcoming traditional cancer treatment limitations, with Likang Life Science focusing on developing personalized tumor vaccines and T-cell therapies [2][3]. Company Overview - Likang Life Science, established in 2017 and based in Beijing Economic and Technological Development Zone, is an innovative biopharmaceutical company dedicated to personalized cancer vaccine and T-cell drug research [2]. - The company is recognized as a national high-tech enterprise and a "specialized and innovative" enterprise in Beijing, with a mission to develop "First in Class" immune cell drugs [2]. Product Development - The company has developed LK101 injection, which integrates AI technology with mRNA-DC vaccine advantages, providing a new treatment pathway for solid tumor patients [3]. - LK101 is created by isolating monocytes from the patient's own white blood cells, inducing them into dendritic cells (DC) in vitro, and then electroporating them with mRNA encoding personalized tumor neoantigens [3][4]. - The product combines the core advantages of mRNA vaccines and DC vaccines, allowing for rapid and efficient expression of multiple antigens and effective activation of tumor-specific T cells [3][4]. Regulatory Approvals - LK101 injection received the first IND clinical approval for an AI+ personalized target mRNA tumor vaccine from the National Medical Products Administration (NMPA) in March 2023 [4]. - It is set to become the first and currently the only product of its kind to receive IND approval from the U.S. Food and Drug Administration (FDA) in February 2025 [4]. - The product also received approval for multi-tumor conversion applications from Hainan Lecheng Medical Products Regulatory Bureau in April 2025, marking it as the first globally approved commercial AI+ personalized target tumor vaccine [4]. Clinical Trial Results - Clinical trials have shown promising safety and efficacy results, with a five-year survival rate of 100% in a postoperative liver cancer patient study conducted in 2018, and no severe drug-related adverse reactions reported [4]. - A Phase I clinical trial for advanced solid tumors initiated in 2023 has completed enrollment, demonstrating sustained disease control effects in late-stage melanoma treatment [4]. Future Directions - Likang Life Science aims to continue advancing clinical trials and commercial expansion, deepening the application of AI technology in target selection and vaccine design, and expanding indications for multiple tumor types and combination treatment plans [5].